Photo: The Hindu
India caps trade margins on anti‑cancer drugs to curb price hikes
TL;DR
- Supreme Court highlighted huge price gaps for cancer medicines
- NPPA announced a 30% cap on trade margins for 137 anti‑cancer drugs
- Cap takes effect on Nov 9 and could lower retail prices
- Policy debate continues over how medicine prices are set in India
The Supreme Court raised concerns in September 2026 about the large disparity between wholesale and retail prices of cancer medicines, citing an example where a drug costing ₹2,700 to a retailer was sold for ₹27,000 to patients.
On October 17, the National Pharmaceutical Pricing Authority announced a 30% limit on trade margins for 137 anti‑cancer drugs, with the rule slated to begin on November 9.
Officials said the margin cap is expected to bring down retail prices for many products, though the overall pricing framework in India remains split between licensing (CDSCO) and price setting (NPPA).
The move has sparked discussion about the need for stronger coordination among regulatory bodies, pharmaceutical firms, and health‑economic experts to address the broader pricing challenge.
Why It Matters
High drug prices affect Indian patients worldwide, including those living in the United States and Canada who may rely on Indian‑manufactured medicines or travel for treatment. The new margin cap aims to reduce retail costs, potentially easing financial strain on families and influencing cross‑border health‑care decisions, while also spotlighting the need for coordinated pricing policies in India.
Nov 2, 2026 · Updated 11/2/2026, 7:50:02 AM · Reported with: The Hindu
Sources (1)
NRI Bytes writes its own articles from the reporting below.
The Hindu — Who decides the cost of medicines in India?Up next · Health
Protecting Your Heart During Winter Morning Walks
Read next →
